A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program

被引:34
作者
Munoz-Fernandez, Santiago [2 ]
Carmona, Loreto [1 ]
Collantes, Eduardo [3 ,4 ]
Mulero, Juan [5 ,6 ]
Jesus Garcia-Yebenes, M. [1 ]
de Miguel, Eugenio [7 ]
Almodovar, Raquel [8 ]
Fernandez-Carballido, Cristina [9 ]
Garcia Llorente, Jose Francisco [10 ]
Gobbo, Milena [1 ]
机构
[1] Soc Espanola Reumatol, Res Unit, Madrid 28001, Spain
[2] Hosp Infanta Sofia, Rheumatol Unit, Madrid, Spain
[3] Hosp Univ Reina Sofia, Dept Rheumatol, Cordoba, Spain
[4] Univ Cordoba, Sch Med, Cordoba, Spain
[5] Hosp Univ Puerta de Hierro Majadahonda, Dept Rheumatol, Madrid, Spain
[6] Univ Autonoma Madrid, Madrid, Spain
[7] Hosp Univ La Paz, Dept Rheumatol, Madrid, Spain
[8] Hosp Univ Fdn Alcorcon, Dept Rheumatol, Madrid, Spain
[9] Hosp Gen Elda, Rheumatol Unit, Elda, Spain
[10] Hosp Basurto, Dept Rheumatol, Basurto, Spain
关键词
ANKYLOSING-SPONDYLITIS; ARTHRITIS; REGISTRY; MULTICENTER; TRIAL; SPAIN;
D O I
10.1136/ard.2010.141200
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the performance of a healthcare programme in early spondyloarthritis (SpA). Methods Based on previous analyses and expectations of a nominal group, the following were set: (1) minimum standards to create early SpA units; (2) standard operating procedures; and (3) eight performance indicators that can be measured in real time using a web-based platform. Results At the end of the evaluation of the programme the expected level of performance was achieved in three of the indicators: 'referral reliability' (standard (S) > 50%, real value (RV) 92%), 'accessibility' (S > 90%, RV=91%) and 'duration of first visit' (S > 50%, RV=53%). The performance in the remaining indicators was inferior: 'success of referral criteria' (S > 50%, RV=28%), 'clinical reports issued' (S > 90%, RV=25%), 'feedback guarantee' (S > 85%, RV=2%), 'missing data' (S < 10%, RV= 24%) and 'frequency of review' (S > 90%, RV=84%). Explanations for the low performance are provided. Conclusions It is possible to implement a large-scale programme that is measurable.
引用
收藏
页码:827 / 830
页数:4
相关论文
共 16 条
[1]   Asistance quality standards in rheumatology [J].
Alonso Ruiz, Alberto ;
Vidal Fuentes, Javier ;
Tornero Molina, Jesus ;
Carbonell Abello, Jordi ;
Lazaro y de Mercado, Pablo ;
Dolores Aguilar Conesa, M. .
REUMATOLOGIA CLINICA, 2007, 3 (05) :218-225
[2]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[3]   The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry [J].
Carbonell, J. ;
Cobo, T. ;
Balsa, A. ;
Descalzo, M. A. ;
Carmona, L. .
RHEUMATOLOGY, 2008, 47 (07) :1088-1092
[4]   Disease pattern of spondyloarthropathies in Spain:: description of the first national registry (REGISPONSER) -: extended report [J].
Collantes, E. ;
Zarco, P. ;
Munoz, E. ;
Juanola, X. ;
Mulero, J. ;
Fernandez-Sueiro, J. L. ;
Torre-Alonso, J. C. ;
Gratacos, J. ;
Gonzalez, C. ;
Batlle, E. ;
Fernandez, P. ;
Linares, L. F. ;
Brito, E. ;
Carmona, L. .
RHEUMATOLOGY, 2007, 46 (08) :1309-1315
[5]  
DESCALZO MA, 2011, REUMATOL CL IN PRESS
[6]   Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis [J].
Feldtkeller, E ;
Khan, MA ;
van der Heijde, D ;
van der Linden, S ;
Braun, J .
RHEUMATOLOGY INTERNATIONAL, 2003, 23 (02) :61-66
[7]  
GOBBO M, 2008, ANN RHEUM DIS S, V67, P385
[8]  
Goëb V, 2009, CLIN EXP RHEUMATOL, V27, pS74
[9]   Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α [J].
Gorman, JD ;
Sack, KE ;
Davis, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1349-1356
[10]   OBJECTIVES AND OUTCOME OF RUNNING AN EARLY INFLAMMATORY ARTHRITIS CLINIC [J].
GOUGH, A ;
YOUNG, A ;
BACON, P .
BAILLIERES CLINICAL RHEUMATOLOGY, 1992, 6 (02) :261-283